JP2007238598A5 - - Google Patents

Download PDF

Info

Publication number
JP2007238598A5
JP2007238598A5 JP2006307035A JP2006307035A JP2007238598A5 JP 2007238598 A5 JP2007238598 A5 JP 2007238598A5 JP 2006307035 A JP2006307035 A JP 2006307035A JP 2006307035 A JP2006307035 A JP 2006307035A JP 2007238598 A5 JP2007238598 A5 JP 2007238598A5
Authority
JP
Japan
Prior art keywords
stroke
patient
composition
composition according
history
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006307035A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007238598A (ja
JP5069448B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2006307035A priority Critical patent/JP5069448B2/ja
Priority claimed from JP2006307035A external-priority patent/JP5069448B2/ja
Publication of JP2007238598A publication Critical patent/JP2007238598A/ja
Publication of JP2007238598A5 publication Critical patent/JP2007238598A5/ja
Application granted granted Critical
Publication of JP5069448B2 publication Critical patent/JP5069448B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2006307035A 2006-02-07 2006-11-13 脳卒中再発予防用組成物 Active JP5069448B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006307035A JP5069448B2 (ja) 2006-02-07 2006-11-13 脳卒中再発予防用組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006029954 2006-02-07
JP2006029954 2006-02-07
JP2006307035A JP5069448B2 (ja) 2006-02-07 2006-11-13 脳卒中再発予防用組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006194043A Division JP4005104B2 (ja) 2006-02-07 2006-07-14 脳卒中再発予防用組成物

Publications (3)

Publication Number Publication Date
JP2007238598A JP2007238598A (ja) 2007-09-20
JP2007238598A5 true JP2007238598A5 (th) 2009-08-20
JP5069448B2 JP5069448B2 (ja) 2012-11-07

Family

ID=38584473

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006307035A Active JP5069448B2 (ja) 2006-02-07 2006-11-13 脳卒中再発予防用組成物

Country Status (1)

Country Link
JP (1) JP5069448B2 (th)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010028067A1 (en) 2008-09-02 2010-03-11 Amarin Corporation Plc Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
SG175390A1 (en) 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
PT3278665T (pt) 2009-04-29 2020-11-19 Amarin Pharmaceuticals Ie Ltd Composição farmacêutica estável e métodos de utilização das mesmas
CN106074486A (zh) 2009-06-15 2016-11-09 阿马里纳药物爱尔兰有限公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl‑c水平的组合物和方法
NZ778131A (en) 2010-11-29 2023-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP4338805B1 (en) 2012-06-29 2025-06-04 Amarin Pharmaceuticals Ireland Limited Eicosapentaenoic acid ethyl ester for use in reducing the risk of non-fatal myocardial infarction in a subject on statin therapy
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
KR20210110890A (ko) 2018-09-24 2021-09-09 애머린 파마슈티칼스 아일랜드 리미티드 대상체에서 심혈관 사건의 위험도를 감소시키는 방법
US12427134B2 (en) 2019-11-12 2025-09-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022713B2 (en) * 2004-02-19 2006-04-04 Kowa Co., Ltd. Hyperlipemia therapeutic agent

Similar Documents

Publication Publication Date Title
JP2007238598A5 (th)
RU2470016C2 (ru) Производное бипиразола
JP2012517449A5 (th)
JP2006504795A5 (th)
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
FI3782612T3 (fi) Sytidiinianalogien oraalisia formulaatioita ja menetelmiä niiden käyttämiseksi
IL191312A0 (en) Oral pharmaceutical dosage form comprising as active ingredients a proton pump inhibitor together with acetyl salicyclic acid
ME02662B (me) Niskofrekventna terapija glatiramer acetatom
UA110012C2 (uk) Лікарські форми для перорального застосування, що містять ацетат лікарбазепіну
WO2007012022A3 (en) Unit dose form with ibuprofen-famotidine admixture
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
HRP20151202T1 (hr) Oralna formulacija metadoksina
BRPI0908052A2 (pt) Composições farmacêuticas de entacapone, levodopa e carbidopa com biodisponibilidade melhorada
RU2009142937A (ru) Тапентадол для лечения в связи с остеоартрозом
HRP20110497T4 (hr) Postupci za primjenu kompozicija aminopiridina sa produženim oslobađanjem
MA28862B1 (fr) Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif
MX2009004579A (es) Composicion farmaceutica que tiene actividad antisicotica, antidepresiva o antiepileptica, con efecto colateral reducido.
WO2008075320A3 (en) Antilipidemic pharmaceutical compositions and process for preparation thereof
JP2008266291A5 (th)
WO2007121545A8 (en) S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions
ATE410152T1 (de) Therapeutisches system mit amoxicillin und clavulansäure
JP2009516719A5 (th)
JP2012097036A5 (th)
WO2006062933A3 (en) Stable compositions of fenofibrate with fatty acid esters
JP2006342148A5 (th)